ArticleFrontiers in endocrinology2024
Role of plasma metabolome in mediating the effect of plasma lipidome on NAFLD: a Mendelian randomization study.
Article in Frontiers in endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Current status survey and risk factor analysis of metabolic dysfunction-associated steatotic liver disease among adolescents in Hainan Province.Scientific reports · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study explored the causal connection among the plasma lipidome, nonalcoholic fatty liver disease (NAFLD), and potential metabolome mediators through Mendelian randomization (MR). Methods: We obtained summary statistics for 179 plasma lipidome traits ( Results: The MR analysis predicted a genetically determined causal relationship between plasma lipidomes and NAFLD. No compelling proof was found that genetically predicted NAFLD influenced the risk of the five plasma lipidomes mentioned earlier. Based on established causal relationships between lipids and metabolites, we identified that eight metabolic pathways are closely associated with NAFLD. Our mediation analysis revealed six mediation relationships, indicating the causal pathway from plasma lipids to NAFLD mediated by five specific metabolites. No potential pleiotropy was found in the sensitivity analysis. Conclusions: In summary, our study identified causal relationships between plasma lipidomes, plasma metabolomes, and NAFLD. Certainly, the impact of plasma lipidomes on NAFLD is not limited to plasma metabolomes, indicating a need to further investigate into other possible mediators. These identified factors may become new biomarkers of the NAFLD contributing to its prevention, diagnosis, and treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.